Abstract:AIM: To investigate pathological types and influential factors of chronic graft dysfunction (CGD) following liver transplantation (LT) in rats.METHODS: The whole experiment was divided into three groups: (1) normal group (n = 12): normal BN rats without any drug or operation; (2) syngeneic transplant group (SGT of BN-BN, n = 12): both donors and recipients were BN rats; and (3) allogeneic transplant group (AGT of LEW-BN, n = 12): Donors were Lewis and recipients were BN rats. In the AGT group, all recipients were subcutaneously injected by Cyclosporin A after LT. Survival time was observed for 1 year. All the dying rats were sampled, biliary tract tissues were performed bacterial culture and liver tissues for histological study. Twenty-one day after LT, 8 rats were selected randomly in each group for sampling. Blood samples from caudal veins were collected for measurements of plasma endotoxin, cytokines and metabonomic analysis, and faeces were analyzed for intestinal microflora.RESULTS: During the surgery of LT, no complications of blood vessels or bile duct happened, and all rats in each group were still alive in the next 2 wk. The long term observation revealed that a total of 8 rats in the SGT and AGT groups died of hepatic graft diseases, 5 rats in which died of chronic bile duct hyperplasia. Compared to the SGT and normal groups, survival ratio of rats significantly decreased in the AGT group (P < 0.01). Moreover, liver necrosis, liver infection, and severe chronic bile duct hyperplasia were observed in the AGT group by H and E stain. On 21 d after LT, compared with the normal group (25.38 +/- 7.09 ng/L) and SGT group (33.12 +/- 10.26 ng/L), plasma endotoxin in the AGT group was remarkably increased (142.86 +/- 30.85 ng/L) (both P < 0.01). Plasma tumor necrosis factor-alpha and interleukin-6 were also significantly elevated in the AGT group (593.6 +/- 171.67 pg/mL, 323.8 +/- 68.30 pg/mL) vs the normal (225.5 +/- 72.07 pg/mL, 114.6 +/- 36.67 pg/mL) and SGT groups (321.3 +/- 88.47 pg/mL, 205.2 +/- 53.06 pg/mL) (P < 0.01). Furthermore, Bacterial cultures of bile duct tissues revealed that the rats close to death from the SGT and AGT groups were strongly positive, while those from the normal group were negative. The analysis of intestinal microflora was performed. Compared to the normal group (7.98 +/- 0.92, 8.90 +/- 1.44) and SGT group (8.51 +/- 0.46, 9.43 +/- 0.69), the numbers of Enterococcus and Enterobactena in the AGT group (8.76 +/- 1.93, 10.18 +/- 1.64) were significantly increased (both P < 0.01). Meanwhile, compared to the normal group (9.62 +/- 1.60, 9.93 +/- 1.10) and SGT group (8.95 +/- 0.04, 9.02 +/- 1.14), the numbers of Bifidobacterium and Lac tobacillus in the AGT group (7.83 +/- 0.72, 8.87 +/- 0.13) were remarkably reduced (both P < 0.01). In addition, metabonomics analysis showed that metabolic profiles of plasma in rats in the AGT group were severe deviated from the normal and SGT groups.CONCLUSION: Chronic bile duct hyperplasia is a pathological type of CGD following LT in rats. The mechanism of this kind of CGD is associated with the alterations of inflammation, intestinal barrier function and microflora as well as plasma metabolic profiles. (c) 2012 Baishideng. All rights reserved.

Exacerbation of Myopathy in Glycogen Debrancher Deficiency After Liver Transplantation: Case Report and Review of the Literature

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?

Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects

Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa

Outcomes of Pediatric Liver Transplantation in Glycogen Storage Disease Type 1b-A Single-Center Experience

Liver and liver cell transplantation for glycogen storage disease type IA

Living Donor Liver Transplantation in Treating Glycogen Storage Disease Type Ⅰ A

Glycogen storage disease type III: a mixed-methods study to assess the burden of disease

Chronic Bile Duct Hyperplasia Is A Chronic Graft Dysfunction Following Liver Transplantation

Glycogen Storage Disease in Adults

Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes

Long‐term personalized high‐protein, high‐fat diet in pediatric patients with glycogen storage disease type IIIa: Evaluation of myopathy, metabolic control, physical activity, growth, and dietary compliance

Glycogen storage disease with massive left ventricular hypertrophy and increased native T1: a case report

Reduced-size liver transplantation for glycogen storage disease.

A case study of a liver transplant-treated patient with glycogen storage disease type Ia presenting with multiple inflammatory hepatic adenomas: an analysis of clinicopathologic and genetic data

Expanding the p.(Arg85Trp) Variant-Specific Phenotype of HNF4A: Features of Glycogen Storage Disease, Liver Cirrhosis, Impaired Mitochondrial Function, and Glomerular Changes

Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome

Congenital Disorder of Glycosylation Type 1T with a Novel Truncated Homozygous Mutation in PGM1 Gene and Literature Review.

Clinical and Functional Characterization of Novel AGL Variants in Two Families with Glycogen Storage Disease Type III

Pathobiology of the Hepatic Glycogen Storage Diseases